Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Application of Quality by Design to the robust preparation of a liposomal GLA formulation by DELOS-susp method

  • Merlo-Mas, Josep
  • Tomsen-Melero, Judit
  • Corchero, José-Luis
  • González-Mira, Elisabet
  • Font, Albert
  • Pedersen, Jannik N.
  • García-Aranda, Natalia
  • Cristóbal-Lecina, Edgar
  • Alcaina-Hernando, Marta
  • Mendoza, Rosa
  • Garcia-Fruitos, Elena
  • Lizarraga, Teresa
  • Resch, Susanne
  • Schimpel, Christa
  • Falk, Andreas
  • Pulido, Daniel
  • Royo, Miriam
  • Schwartz Jr., Simó
  • Abasolo, Ibane
  • Pedersen, Jan Skov
  • Danino, Dganit
  • Soldevila, Andreu
  • Veciana, Jaume
  • Sala, Santi
  • Ventosa, Nora
  • Córdoba, Alba
Fabry disease is a lysosomal storage disease arising from a deficiency of the enzyme α-galactosidase A (GLA). The enzyme deficiency results in an accumulation of glycolipids, which over time, leads to cardiovascular, cerebrovascular, and renal disease, ultimately leading to death in the fourth or fifth decade of life. Currently, lysosomal storage disorders are treated by enzyme replacement therapy (ERT) through the direct administration of the missing enzyme to the patients. In view of their advantages as drug delivery systems, liposomes are increasingly being researched and utilized in the pharmaceutical, food and cosmetic industries, but one of the main barriers to market is their scalability. Depressurization of an Expanded Liquid Organic Solution into aqueous solution (DELOS-susp) is a compressed fluid-based method that allows the reproducible and scalable production of nanovesicular systems with remarkable physicochemical characteristics, in terms of homogeneity, morphology, and particle size. The objective of this work was to optimize and reach a suitable formulation for in vivo preclinical studies by implementing a Quality by Design (QbD) approach, a methodology recommended by the FDA and the EMA to develop robust drug manufacturing and control methods, to the preparation of α-galactosidase-loaded nanoliposomes (nanoGLA) for the treatment of Fabry disease. Through a risk analysis and a Design of Experiments (DoE), we obtained the Design Space in which GLA concentration and lipid concentration were found as critical parameters for achieving a stable nanoformulation. This Design Space allowed the optimization of the process to produce a nanoformulation suitable for in vivo preclinical testing., info:eu-repo/semantics/publishedVersion
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Synthesis of Stable Cholesteryl–Polyethylene Glycol–Peptide Conjugates with Non-Disperse Polyethylene Glycol Lengths

  • Cristóbal-Lecina, Edgar
  • Pulido, Daniel
  • Martin-Malpartida, Pau
  • Macías, María J.
  • Albericio, Fernando
  • Royo, Miriam
A method for conjugating cholesterol to peptide ligands through non-disperse polyethylene glycol (ND-PEG) through a non-hydrolysable linkage is described. The iterative addition of tetraethylene glycol macrocyclic sulfate to cholesterol (Chol) renders a family of highly pure well-defined Chol-PEG compounds with different PEG lengths from 4 up to 20 ethylene oxide units, stably linked through an ether bond. The conjugation of these Chol-PEG compounds to the cyclic (RGDfK) peptide though Lys5 side chains generates different lengths of Chol-PEG-RGD conjugates that retain the oligomer purity of the precursors, as analysis by HRMS and NMR has shown. Other derivatives were synthesized with similar results, such as Chol-PEG-OCH3 and Chol-PEG conjugated to glutathione and Tf1 peptides through maleimide–thiol chemoselective ligation. This method allows the systematic synthesis of highly pure uniform stable Chol-PEGs, circumventing the use of activation groups on each elongation step and thus reducing the number of synthesis steps., We thank M. Dí az and M. Vilaseca (Mass Spectrometry Core Facility, IRB Barcelona) for the support with the MS data and the Peptide Synthesis Unit (U3) of Nanbiosis ICTS. This work was supported by the Spanish Government (no. RTC-2014- 2207-1, Centers of Excellence Severo Ochoa), CIBER-BBN (Lipocell, no. CB06-01-0074), European Community Horizon 2020 (Smart4Fabry, no. 720942), IRB Barcelona, BBVA foundation (M.J.M.), and Generalitat de Catalunya (nos. 2017-SGR-1439 and 2017-SGR-50 and the CERCA Programme). M.J.M. is an ICREA Programme Investigator., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Application of Quality by Design to the robust preparation of a liposomal GLA formulation by DELOS-susp method

  • Merlo Mas, Josep
  • Tomsen Melero, Judit
  • Corchero, José Luis
  • González Mira, Elisabet
  • Font, Albert
  • Pedersen, Jannik N.
  • García Aranda, Natalia
  • Cristóbal Lecina, Edgar
  • Alcaina-Hernando, Marta
  • Mendoza, Rosa
  • García Fruitós, Elena
  • Lizarraga, Teresa
  • Resch, Susanne
  • Schimpel, Christa
  • Falk, Andreas
  • Pulido, Daniel
  • Royo, Miriam
  • Schwartz Jr., Simó
  • Córdoba, Alba
Fabry disease is a lysosomal storage disease arising from a deficiency of the enzyme α-galactosidase A (GLA). The enzyme deficiency results in an accumulation of glycolipids, which over time, leads to cardiovascular, cerebrovascular, and renal disease, ultimately leading to death in the fourth or fifth decade of life. Currently, lysosomal storage disorders are treated by enzyme replacement therapy (ERT) through the direct administration of the missing enzyme to the patients. In view of their advantages as drug delivery systems, liposomes are increasingly being researched and utilized in the pharmaceutical, food and cosmetic industries, but one of the main barriers to market is their scalability. Depressurization of an Expanded Liquid Organic Solution into aqueous solution (DELOS-susp) is a compressed fluid-based method that allows the reproducible and scalable production of nanovesicular systems with remarkable physicochemical characteristics, in terms of homogeneity, morphology, and particle size. The objective of this work was to optimize and reach a suitable formulation for in vivo preclinical studies by implementing a Quality by Design (QbD) approach, a methodology recommended by the FDA and the EMA to develop robust drug manufacturing and control methods, to the preparation of α-galactosidase-loaded nanoliposomes (nanoGLA) for the treatment of Fabry disease. Through a risk analysis and a Design of Experiments (DoE), we obtained the Design Space in which GLA concentration and lipid concentration were found as critical parameters for achieving a stable nanoformulation. This Design Space allowed the optimization of the process to produce a nanoformulation suitable for in vivo preclinical testing., The authors acknowledge the financial support from European Commission through H2020 program of the Smart-4-Fabry project (ID 720942). We acknowledge financial support to our research from Instituto de Salud Carlos III, through “Acciones CIBER”. The Networking Research Center on Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN) is 2008–2011, financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund. Authors acknowledge financial support from the Agencia Estatal de Investigación-Ministerio de Ciencia e Innovación through the “Severo Ochoa” Programme for Centres of Excellence in R & D (CEX2019-000917-S). This work was also financed by 1084 the Ministerio de Ciencia e Innovación (PID2019-105622RB-1085 I00). We also thank the denomination of the 1101 consolidated group from Generalitat de Catalunya: 2017-1102 SGR-1439 (M.R.) and 2017-SGR-918 (J.V.). We also acknowledge the ICTS “NANBIOSIS”, more specifically the support from the Protein Production Platform of CIBER-BBN/IBB, at the UAB SepBioES scientific-technical service (www.nanbiosis.es/unit/u1-proteinproduction-platform-ppp/), the Soft Materials Service linked to Biomaterial Processing and Nanostructuring Unit at ICMAB-CSIC (www.nanbiosis.es/portfolio/u6-biomaterial-processing-and-nanostructuring-unit/) and the Peptide Synthesis unit at the IQAC-CSIC (www.nanbiosis.es/portfolio/u3-synthesis-of-peptides-unit/). N. A-G. is supported by a PERIS grant from the Catalan Government (SLT006/17/270). J. T-M. is supported by a FI-AGAUR grant from the Catalan Government and the European Social Fund (ESF-Investing in your future) of the European Union. This work has been done in the framework of the JT-M. doctorate in Materials Science of the Universitat Autònoma de Barcelona. The technical assistance of Inbal Ionita, Ella Kesselman and Mingming Zhang from Technion - Israel Institute of Technology; and Ramon González from ICMAB-CSIC is acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Impact of Chemical Composition on the Nanostructure and Biological Activity of α-Galactosidase-Loaded Nanovesicles for Fabry Disease Treatment

  • Tomsen Melero, Judit
  • Passemard, Solène
  • García Aranda, Natalia
  • Díaz Riascos, Zamira Vanessa
  • González Rioja, Ramon
  • Nedergaard Pedersen, Jannik
  • Lyngsø, Jeppe
  • Merlo Mas, Josep
  • Cristóbal Lecina, Edgar
  • Corchero, José Luis
  • Pulido, Daniel
  • Cámara Sánchez, Patricia
  • Portnaya, Irina
  • Ionita, Inbal
  • Schwartz Jr., Simó
  • Veciana, Jaume
  • Sala Vergés, Santiago
  • Royo, Miriam
  • Córdoba, Diego
  • Danino, Dganit
  • Pedersen, Jan Skov
  • González Mira, Elisabet
  • Abasolo, Ibane
  • Ventosa, Nora
Fabry disease is a rare lysosomal storage disorder characterized by a deficiency of α-galactosidase A (GLA), a lysosomal hydrolase. The enzyme replacement therapy administering naked GLA shows several drawbacks including poor biodistribution, limited efficacy, and relatively high immunogenicity in Fabry patients. An attractive strategy to overcome these problems is the use of nanocarriers for encapsulating the enzyme. Nanoliposomes functionalized with RGD peptide have already emerged as a good platform to protect and deliver GLA to endothelial cells. However, low colloidal stability and limited enzyme entrapment efficiency could hinder the further pharmaceutical development and the clinical translation of these nanoformulations. Herein, the incorporation of the cationic miristalkonium chloride (MKC) surfactant to RGD nanovesicles is explored, comparing two different nanosystems—quatsomes and hybrid liposomes. In both systems, the positive surface charge introduced by MKC promotes electrostatic interactions between the enzyme and the nanovesicles, improving the loading capacity and colloidal stability. The presence of high MKC content in quatsomes practically abolishes GLA enzymatic activity, while low concentrations of the surfactant in hybrid liposomes stabilize the enzyme without compromising its activity. Moreover, hybrid liposomes show improved efficacy in cell cultures and a good in vitro/in vivo safety profile, ensuring their future preclinical and clinical development., This work was supported by the financial support from European Commission through the H2020 program (Smart-4-Fabry project, ID 720942). The Networking Research Centre on Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN) is financed by the Instituto de Salud Carlos III (ISCIII) with assistance from the European Regional Development Fund (ERDF). This work was also financed by the Ministerio de Ciencia e Innovación (PID2019-105622RB-I00). The work was also partially funded by ISCIII (PI18_00871 cofounded by ERDF) and CIBER-BBN (EXPLORE) granted to I.A. We also acknowledge the ICTS “NANBIOSIS”, more specifically, the support from the Protein Production Platform of CIBER-BBN/IBB, at the UAB SepBioES scientific-technical service (https://www.nanbiosis.es/portfolio/u1-protein-production-platform-ppp/), the Soft Materials Service linked to Biomaterial Processing and Nanostructuring Unit (U6) at ICMAB-CSIC (www.nanbiosis.es/portfolio/u6-biomaterial-processing-and-nanostructuring-unit/), the Synthesis of Peptide Unit (U3) at the IQAC-CSIC (www.nanbiosis.es/portfolio/u3-synthesis-of-peptides-unit/), and the In Vivo Experimental Platform of the Functional Validation & Preclinical Research (FVPR) area (http://www.nanbiosis.es/portfolio/u20-in-vivo-experimental-platform/). We also thank the denomination of the consolidated group from Generalitat de Catalunya: 2017-SGR-1439 (M.R.) and 2017-SGR-918 (J.V.). J.T.-M. thanks the financial support by the FI-AGAUR grant by the Generalitat de Catalunya, especially the Secretary of Universities and Research of the Department of Business and Knowledge of the Generalitat de Catalunya and the European Social Fund (ESF–Investing in your future) of the European Union. This work has been done in the framework of the J.T.-M. doctorate in Materials Science of the Universitat Autònoma de Barcelona. N.G.-A. is supported by a PERIS grant from the Catalan Government (SLT006/17/270). Authors acknowledge financial support from the Agencia Estatal de Investigación-Ministerio de Ciencia e Innovación through the “Severo Ochoa” Programme for Centres of Excellence in R&D (CEX2019-000917-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Hierarchical Quatsome-RGD Nanoarchitectonic Surfaces for Enhanced Integrin-Mediated Cell Adhesion

  • Martínez Miguel, Marc
  • Castellote Borrell, Miquel
  • Köber, Mariana
  • Kyvik Ruiz, Adriana
  • Tomsen Melero, Judit
  • Vargas Nadal, Guillem
  • Muñoz Martín, José M.
  • Pulido, Daniel
  • Cristóbal Lecina, Edgar
  • Passemard, Solène
  • Royo, Miriam
  • Mas Torrent, Marta
  • Veciana, Jaume
  • Giannotti, Marina I.
  • Guasch, Judit
  • Ventosa, Nora
  • Ratera, Immaculada
The synthesis and study of the tripeptide Arg-Gly-Asp (RGD), the binding site of different extracellular matrix proteins, e.g., fibronectin and vitronectin, has allowed the production of a wide range of cell adhesive surfaces. Although the surface density and spacing of the RGD peptide at the nanoscale have already shown a significant influence on cell adhesion, the impact of its hierarchical nanostructure is still rather unexplored. Accordingly, a versatile colloidal system named quatsomes, based on fluid nanovesicles formed by the self-assembling of cholesterol and surfactant molecules, has been devised as a novel template to achieve hierarchical nanostructures of the RGD peptide. To this end, RGD was anchored on the vesicle's fluid membrane of quatsomes, and the RGD-functionalized nanovesicles were covalently anchored to planar gold surfaces, forming a state of quasi-suspension, through a long poly(ethylene glycol) (PEG) chain with a thiol termination. An underlying self-assembled monolayer (SAM) of a shorter PEG was introduced for vesicle stabilization and to avoid unspecific cell adhesion. In comparison with substrates featuring a homogeneous distribution of RGD peptides, the resulting hierarchical nanoarchitectonic dramatically enhanced cell adhesion, despite lower overall RGD molecules on the surface. The new versatile platform was thoroughly characterized using a multitechnique approach, proving its enhanced performance. These findings open new methods for the hierarchical immobilization of biomolecules on surfaces using quatsomes as a robust and novel tissue engineering strategy., This work was supported by MICINN (PID2019-105622RBI00, MAT2016-80826-R, PID2019-111682RB-I00, PID2020-115296RA-I00, CTQ2015-66194-R; SAF2014-60138-R, RTI2018-093831-B-I00, and PDC2021-121481-I00); Instituto de Salud Carlos III (ISCIII) through the Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN (FlexQS-skin, FlexCAB, BBN18PI01, BBN20PIV02, and CB/06/0074); Generalitat de Catalunya (grants 2017-SGR-918, 2017-SGR-229, 2017-SGR-1442, 2017-SGR-1439); the Fundació Marató de TV3 (Nr. 201812); the COST Action CA15126 Between Atom and Cell, and “ERDF A way of making Europe”. J.G. acknowledges financial support from the Ramón y Cajal Program (RYC-2017-22614) from MICINN and the Max Planck Society through the Max Planck Partner Group “Dynamic Biomimetics for Cancer Immunotherapy” in collaboration with the Max Planck Institute for Medical Research (Heidelberg, Germany). This work has received funding from the European Union’s Horizon 2020 research and innovation program through grant agreements 953110 (PHOENIX), 720942 (Smart4Fabry), 101007804 (MICRO4NANO), and 801342 (granted to the Agency for Business Competitiveness ACCIÓ through a Tecniospring Industry fellowship (TECSPR19-1-0065)). ICMAB acknowledges support from MICINN through the “‘Severo Ochoa”’ Programme for Centres of Excellence in R&D (CEX2019-000917-S). J.M. acknowledges a “Juan de la Cierva” fellowship from MICINN. J.T-M. acknowledges an FI-AGAUR grant (2020FI_B2 00137) from Generalitat de Catalunya and the European Social Fund. We also acknowledge the ICTS “NANBIOSIS for the support of the Synthesis of Peptides Unit (U3) at IQAC–CSIC (https://www.nanbiosis.es/portfolio/u3-synthesis-of-peptides-unit/) and the Biomaterial Processing and Nanostructuring Unit (U6) at ICMAB-CSIC (https://www.nanbiosis.es/portfolio/u6-biomaterial-processing-and-nanostructuring-unit/). We are grateful to the SMP unit of the Scientific and Technological Centers of University of Barcelona (CCiTUB). This work has been developed under the “Biochemistry, Molecular Biology and Biomedicine” and “Materials Science” Ph.D. programs of Universitat Autònoma de Barcelona (UAB)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2019-000917-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Liposomal formulations for treating lysosomal storage disorders

  • Tomsen Melero, Judit
  • Merlo Mas, Josep
  • Carreño, Aida
  • Sala Vergés, Santiago
  • Córdoba, Alba
  • Veciana, Jaume
  • González Mira, Elisabet
  • Ventosa, Nora
Lysosomal storage disorders (LSD) are a group of rare life-threatening diseases caused by a lysosomal dysfunction, usually due to the lack of a single enzyme required for the metabolism of macromolecules, which leads to a lysosomal accumulation of specific substrates, resulting in severe disease manifestations and early death. There is currently no definitive cure for LSD, and despite the approval of certain therapies, their effectiveness is limited. Therefore, an appropriate nanocarrier could help improve the efficacy of some of these therapies. Liposomes show excellent properties as drug carriers, because they can entrap active therapeutic compounds offering protection, biocompatibility, and selectivity. Here, we discuss the potential of liposomes for LSD treatment and conduct a detailed analysis of promising liposomal formulations still in the preclinical development stage from various perspectives, including treatment strategy, manufacturing, characterization, and future directions for implementing liposomal formulations for LSD., This work has received funding from: Grant Severo Ochoa CEX2019-000917-S funded by Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación MCIN/AEI/10.13039/501100011033; Project MOL4BIO PID2019-105622RB-I00 funded by Agencia Estatal de Investigación - Ministerio de Ciencia e Innovación MCIN/AEI/10.13039/501100011033; Project PHOENIX-OITB funded by European Union’s Horizon 2020 research and innovation programme under grant agreement No 953110; Project SMART4FABRY funded by European Union’s Horizon 2020 research and innovation programme under grant agreement No 720942. The authors are also grateful to the Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2019-000917-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeted nanoliposomes to improve enzyme replacement therapy of Fabry disease

  • Tomsen-Melero, Judit
  • Moltó-Abad, Marc
  • Merlo-Mas, Josep
  • Díaz-Riascos, Zamira V.
  • Cristóbal-Lecina, Edgar
  • Soldevila, Andreu
  • Altendorfer-Kroath, Thomas
  • Danino, Dganit
  • Ionita, Inbal
  • Pedersen, Jan Skov
  • Snelling, Lyndsey
  • Clay, Hazel
  • Carreño, Aida
  • Corchero, José L.
  • Pulido, Daniel
  • Casas, Josefina
  • Veciana, Jaume
  • Schwartz, Simó
  • Sala, Santi
  • Font, Albert
  • Birngruber, Thomas
  • Royo, Miriam
  • Córdoba, Alba
  • Ventosa, Nora
  • Abasolo, Ibane
  • González-Mira, Elisabet
The central nervous system represents a major target tissue for therapeutic approach of numerous lysosomal storage disorders. Fabry disease arises from the lack or dysfunction of the lysosomal alpha-galactosidase A (GLA) enzyme, resulting in substrate accumulation and multisystemic clinical manifestations. Current enzyme replacement therapies (ERTs) face limited effectiveness due to poor enzyme biodistribution in target tissues and inability to reach the brain. We present an innovative drug delivery strategy centered on a peptide-targeted nanoliposomal formulation, designated as nanoGLA, engineered to selectively deliver a recombinant human GLA (rhGLA) to target tissues. In a Fabry mouse model, nanoGLA demonstrated improved efficacy, inducing a notable reduction in Gb3 deposits in contrast to non-nanoformulated GLA, even in the brain, highlighting the potential of the nanoGLA to address both systemic and cerebrovascular manifestations of Fabry disease. The EMA has granted the Orphan Drug Designation to this product, underscoring the potential clinical superiority of nanoGLA over authorized ERTs and encouraging to advance it toward clinical translation., This work was supported by the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 720942 (SMART4FABRY); the European Union’s Horizon 2020 research and innovation programme 953110 PHOENIX-OITB (to J.T.-M., J.M.-M., A.S., A.Ca., A.F., S.Sa., A.Có., N.V., and E.G.-M.); European Union EIC Transition, 101136772 Nano4Rare (to J.T.-M., A.Ca., N.V., and E.G.-M.); the Generalitat de Catalunya, FI-AGAUR, Secretary of Universities and Research of the Department of Business and Knowledge of the Generalitat de Catalunya and the European Social Fund (ESF–Investing in your future) of the European Union (to J.T.-M.); CIBER-BBN, EXPLORE-3, and PEGLyso-2 project (to I.A.); the Instituto de Salud Carlos III grants PI18/00871 and PI21/00936, cofounded by European Regional Development Fund (to I.A.); Catalan Government’s Strategic Plan for Research and Innovation in Health, PERIS, SLT01720000181 (to M.M.-A.); the Generalitat de Catalunya, 2017 SGR 1439 and 2021 SGR 00230 (to E.C.-L., D.P., and M.R.), 2021 SGR 1173 (to I.A.), and 2021 SGR 00438 (to J.T.-M., A.Ca., J.V., N.V., and E.G.-M.); Generalitat de Catalunya, AGAUR, 2021 INNOV 00053 (to J.T.-M., A.Ca., N.V., and E.G.-M.); the Ministerio de Ciencia e Innovación, Plan Estatal de Investigación Científica y Técnica y de Innovación (PEICTI) 2021–2023, PID2022-137332OB-I00 (ARMONIA) (to J.T.-M., A.Ca., N.V., and E.G.-M.); and the Ministerio de Ciencia e Innovación, Severo Ochoa Programme, CEX2019-000917-S (FUNFUTURE) and CEX2023-001263-S (to J.T.-M., A.Ca., N.V., and E.G.-M.)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Application of Quality by Design to the robust preparation of a liposomal GLA formulation by DELOS-susp method

  • Merlo-Mas, Josep
  • Tomsen-Melero, Judit
  • Corchero, José-Luis
  • González-Mira, Elisabet
  • Font, Albert
  • Pedersen, Jannik N.
  • García-Aranda, Natalia
  • Cristóbal-Lecina, Edgar
  • Alcaina-Hernando, Marta
  • Mendoza, Rosa
  • Garcia-Fruitos, Elena
  • Lizarraga, Teresa
  • Resch, Susanne
  • Schimpel, Christa
  • Falk, Andreas
  • Pulido, Daniel
  • Royo, Miriam
  • Schwartz Jr., Simó
  • Abasolo, Ibane
  • Pedersen, Jan Skov
  • Danino, Dganit
  • Soldevila, Andreu
  • Veciana, Jaume
  • Sala, Santi
  • Ventosa, Nora
  • Córdoba, Alba
Fabry disease is a lysosomal storage disease arising from a deficiency of the enzyme α-galactosidase A (GLA). The enzyme deficiency results in an accumulation of glycolipids, which over time, leads to cardiovascular, cerebrovascular, and renal disease, ultimately leading to death in the fourth or fifth decade of life. Currently, lysosomal storage disorders are treated by enzyme replacement therapy (ERT) through the direct administration of the missing enzyme to the patients. In view of their advantages as drug delivery systems, liposomes are increasingly being researched and utilized in the pharmaceutical, food and cosmetic industries, but one of the main barriers to market is their scalability. Depressurization of an Expanded Liquid Organic Solution into aqueous solution (DELOS-susp) is a compressed fluid-based method that allows the reproducible and scalable production of nanovesicular systems with remarkable physicochemical characteristics, in terms of homogeneity, morphology, and particle size. The objective of this work was to optimize and reach a suitable formulation for in vivo preclinical studies by implementing a Quality by Design (QbD) approach, a methodology recommended by the FDA and the EMA to develop robust drug manufacturing and control methods, to the preparation of α-galactosidase-loaded nanoliposomes (nanoGLA) for the treatment of Fabry disease. Through a risk analysis and a Design of Experiments (DoE), we obtained the Design Space in which GLA concentration and lipid concentration were found as critical parameters for achieving a stable nanoformulation. This Design Space allowed the optimization of the process to produce a nanoformulation suitable for in vivo preclinical testing., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Application of Quality by Design to the robust preparation of a liposomal GLA formulation by DELOS-susp method

  • Merlo-Mas, Josep
  • Tomsen Melero, Judit|||0000-0002-2837-8107
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
  • González Mira, Elisabet
  • Font, Albert|||0000-0003-3908-1111
  • Pedersen, Jannik N.
  • García Aranda, Natalia|||0000-0003-3230-9881
  • Cristóbal-Lecina, Edgar
  • Alcaina Hernando, Marta
  • Mendoza Moreno, Rosa|||0000-0002-0488-4814
  • Garcia-Fruitos, Elena|||0000-0001-7498-4864
  • Lizarraga, Teresa
  • Resch, Susanne
  • Schimpel, Christa
  • Falk, Andreas
  • Pulido, Daniel|||0000-0002-2841-194X
  • Royo, Miriam|||0000-0001-5292-0819
  • Schwartz, Simon|||0000-0001-8297-7971
  • Abasolo, Ibane|||0000-0001-5970-6276
  • Pedersen, Jan Skov|||0000-0002-7768-0206
  • Danino, Dganit
  • Soldevila, Andreu
  • Veciana i Miró, Jaume|||0000-0003-1023-9923
  • Sala, Santi
  • Ventosa, Nora|||0000-0002-8008-4974
  • Córdoba, Alba
Fabry disease is a lysosomal storage disease arising from a deficiency of the enzyme α-galactosidase A (GLA). The enzyme deficiency results in an accumulation of glycolipids, which over time, leads to cardiovascular, cerebrovascular, and renal disease, ultimately leading to death in the fourth or fifth decade of life. Currently, lysosomal storage disorders are treated by enzyme replacement therapy (ERT) through the direct administration of the missing enzyme to the patients. In view of their advantages as drug delivery systems, liposomes are increasingly being researched and utilized in the pharmaceutical, food and cosmetic industries, but one of the main barriers to market is their scalability. Depressurization of an Expanded Liquid Organic Solution into aqueous solution (DELOS-susp) is a compressed fluid-based method that allows the reproducible and scalable production of nanovesicular systems with remarkable physicochemical characteristics, in terms of homogeneity, morphology, and particle size. The objective of this work was to optimize and reach a suitable formulation for in vivo preclinical studies by implementing a Quality by Design (QbD) approach, a methodology recommended by the FDA and the EMA to develop robust drug manufacturing and control methods, to the preparation of α-galactosidase-loaded nanoliposomes (nanoGLA) for the treatment of Fabry disease. Through a risk analysis and a Design of Experiments (DoE), we obtained the Design Space in which GLA concentration and lipid concentration were found as critical parameters for achieving a stable nanoformulation. This Design Space allowed the optimization of the process to produce a nanoformulation suitable for in vivo preclinical testing.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Human α-galactosidase a mutants, Priceless tools to develop novel therapies for fabry disease

  • Modrego, Andrea
  • Amaranto, Marilla
  • Godino, Agustina
  • Mendoza, Rosa|||0000-0002-0488-4814
  • Barra, José Luis
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
Fabry disease (FD) is a lysosomal storage disease caused by mutations in the gene for the α-galactosidase A (GLA) enzyme. The absence of the enzyme or its activity results in the accumulation of glycosphingolipids, mainly globotriaosylceramide (Gb3), in different tissues, leading to a wide range of clinical manifestations. More than 1000 natural variants have been described in the GLA gene, most of them affecting proper protein folding and enzymatic activity. Currently, FD is treated by enzyme replacement therapy (ERT) or pharmacological chaperone therapy (PCT). How-ever, as both approaches show specific drawbacks, new strategies (such as new forms of ERT, or-gan/cell transplant, substrate reduction therapy, or gene therapy) are under extensive study. In this review, we summarize GLA mutants described so far and discuss their putative application for the development of novel drugs for the treatment of FD. Unfavorable mutants with lower activities and stabilities than wild-type enzymes could serve as tools for the development of new pharmacological chaperones. On the other hand, GLA mutants showing improved enzymatic activity have been identified and produced in vitro. Such mutants could overcome several complications associated with current ERT, as lower-dose infusions of these mutants could achieve a therapeutic effect equiv-alent to that of the wild-type enzyme.